TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: NMES to Improve Eyelid Functions in Cranial Nerve (CN) III and VII Palsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cranial nerve III (oculomotor nerve) and/or cranial nerve IV (facial nerve) palsy.~* Able to read and communicate in English.~Exclusion Criteria:~* Idiopathic onset of CN III and/or CN IV palsy.~* Traumatic injury to the eye or eyelid.~* Active wounds in the treatment area.~* Presence of swelling or infection in or surrounding the affected eye.~* Diminished sensation in the area to be treated.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EyeStim Group (Type: EXPERIMENTAL): Receive an active NMES treatment to the targeted muscles controlling eyelid function.
- Control Group (Type: SHAM_COMPARATOR): Undergo all the same procedures as the EyeStim group except receive a sham NMES treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
INCLUSION CRITERIA:~* 2 - 18 years of age~* SOJRA for at least 3 months, with stable systemic features~* If taking methotrexate, hydroxychloroquine, or NSAIDs, dose must be stable~* Must take prednisone at a stable dose~EXCLUSION CRITERIA:~* Need for other DMARDs or prestudy requirements for oral or parenteral pulse steroids or intra-articular steroids~* Pregnant or nursing female~* Clinically significant abnormal laboratory test results for blood cells, liver or kidney function, or serology~* Previous receipt of any tumor necrosis factor (TNF) inhibitor~* Live virus vaccine within 12 weeks of study entry~* Participation in another study requiring informed consent within 12 weeks of entry~* Diabetes that requires insulin treatment~* Infection, chronic, recurrent, or currently active~* Any serious medical or psychiatric condition or history of alcohol or drug abuse

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: Etanercept (Type: EXPERIMENTAL): Participants received 0.4 mg/kg etanercept administered subcutaneously twice a week for up to 6 months in Part 1A.~Participants who had a partial response entered Part 1B and received 0.8 mg/kg etanercept twice weekly for up to 4 months.
- Part 2: Placebo (Type: PLACEBO_COMPARATOR): Participants who met response criteria in Part 1 were randomized to receive placebo twice a week for up to 3 months.
- Part 2: Etanercept (Type: EXPERIMENTAL): Participants who met response criteria in Part 1 were randomized to continue receiving etanercept twice a week at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to 3 months.
- Part 3: (Type: EXPERIMENTAL): Participants who experienced a flare or completed 3 months of treatment in Part 2 entered Part 3 and received open-label treatment with etanercept at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to a maximum of 12 months, including treatment in Part 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Surgical or Catheter Ablation of Lone Atrial Fibrillation (AF) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has documented Paroxysmal AF as defined by the ACC/AHA/ESC guidelines~* Minimal one documented AF episode in the last 6 months~* Refractory to minimal two Class I or III anti-arrhythmic drug~* Age \> 18 years~* Signed and dated the Patient Informed Consent.~* Patient can tolerate anti-coagulation therapy (Warfarin/Coumadin)~Exclusion Criteria:~* Patient has a structural heart disease~* Ejection fraction \< 40 %~* Echocardiographic evidence for a left atrium \> 45 mm (parasternal axis)~* Patients on amiodarone, or patients known to be intolerant for amiodarone~* Dextrocardia, current endocarditis, systemic infection, renal failure~* Patient has known cerebrovascular disease, including a history of stroke, CVA or TIA~* Pregnancy at enrolment; or planned pregnancy within the follow up period~* Patient has a life expectancy less than 1 year~* The subject is participating in another device or drug study~* The patient is unable and/or unwilling to cooperate with study procedures or required follow up visits~* Echocardiographic (TTE) evidence for presence of left atrial thrombus~* Previous (cardio-) thoracic surgery~* Previous left atrial ablation~* Patients with permanent or persistent AF

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Arm 1: Catheter Ablation
- 2 (Type: ACTIVE_COMPARATOR): Arm 2: Surgical Ablation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a severe closed head injury and a post-resuscitation Glasgow Coma Scale (GCS) score below or equal to 8~* Age between 15 and 76 years (inclusive)~* High ICP (\> 20 mm Hg) refractory to first-tier therapeutic measures according to BTF guidelines (1)~* Hemodynamic stability defined as a systolic blood pressure of at least 100 mm Hg or above at the moment of entering the trial~* Written informed consent obtained from next-of-kin or the patient's legally authorized representative~Exclusion Criteria:~* Previously known ischemic heart failure (Ejection fraction \< 35%)~* Pregnancy~* bilateral dilated and unreactive pupils and a GCS of 3~* Intolerance to barbiturates

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Pentobarbital
- 2 (Type: ACTIVE_COMPARATOR): thiopental

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years~* Diagnosed as hypoactive delirium~* Informed consent given~Exclusion Criteria:~* Pregnancy~* Epilepsy~* M. Parkinson~* Lewy-body dementia~* Prolonged QT-time~* Known allergy to the medicinals used~* Renal replacement therapy~* Hepatic encephalopathy~* Hyperthyroid~* Glaucoma~* Previous suicide attempts~* Syndrome of Gilles de la Tourette~* Patients which cannot receive the medication oral or through a nasogastric tube

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): No intervention
- 2 (Type: EXPERIMENTAL): Methylphenidate
- 3 (Type: EXPERIMENTAL): Rivastigmine
- 4 (Type: EXPERIMENTAL): Haloperidol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transmural Systems Transcaval Closure Device for Transcaval Access Ports During Transcatheter Aortic Valve Replacement

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Consents to participate in this study and all related clinical follow-up procedures~* Adults age greater than or equal to 21 years~* Undergoing transcatheter aortic valve replacement (TAVR) based on the clinical assessment of the multidisciplinary heart team~* Ineligible for femoral artery access for the selected transcatheter heart valve (THV) according to the THV manufacturer instructions for use. (Note Corevalve Evolut R: greater than or equal to 5mm; Evolut PRO 23, 26, 29 mm valves and Evolut R 34 mm: greater than or equal to 5.5 mm; Edwards Sapien 3, 23-26mm: 5.5 mm; Edwards Sapien 3, 29mm: 6.0mm; Anatomic ineligibility also considers patient-specific pattern of iliofemoral calcium and tortuosity.)~* Eligible for transcaval access based on Core lab analysis of the baseline abdomen/pelvis CT indicating a calcium-free target window on the abdominal aorta; a target greater than or equal to 15mm from the lowest main renal artery or aorto-iliac bifurcation; no important interposed structures; a projected intravascular centerline distance from the lower femoral head to the target at least 5cm less than the intended THV introducer sheath; patient celiac or superior mesenteric artery~* Aorta diameter greater than or equal to 11mm at the target crossing site~* Concordance of the study eligibility committee~EXCLUSION CRITERIA:~* High risk features on baseline CT including porcelain aorta (confluent calcification); pedunculated aortic atheroma; or leftward aortic angel greater than or equal to 20 degrees with regard to vertical.~* Renal dysfunction limiting follow-up contrast-enhanced CR (estimated glomerular filtration rate, eGFR less than 30mL/min/1.73m\^2 if not already on renal replacement therapy)~* Pregnancy or intent to become pregnant prior to completion of all protocol follow-up procedures

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transcaval access and closure with the transcaval closure device (TCD) test article. (Type: EXPERIMENTAL): All participants undergo transcaval access for transcatheter aortic valve replacement (TAVR) followed by implantation of the transcaval closure device (TCD).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Benefit of Systematic Proposition of Nicotine Substitution for Patients Undergoing Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who smokes at least one cigarette or cannabis joint per day, every day~* Patient received for nurse consultation at least 48 hours before surgery~* Patient planned to undergo surgery, with entry the day of surgery and 1 day of post-operative hospitalisation~* Patient in physical capacity and willing to undergo exhaled carbon monoxide measurement~* For patients with one of the following chronic diseases: diabetes, Chronic Obstructive Pulmonary Disease, glucose intolerance, hemolytic anemia, asthma and dilation of the bronchi, these diseases must be stable~* Signature of the specific study informed consent~* Patient affiliated or beneficiary of social security system~Exclusion Criteria:~* Inability to submit to study follow-up for geographic, social or psychological reasons~* Patient already included in an interventional clinical research protocol~* Patients protected by French law from clinical research inclusion (pregnant, in labour, breastfeeding, legally protected, under judiciary or administrative liberty deprivation)~* Patient using nicotine substitutes before the nurse consultation~* Alcohol consumption six hours before the exhaled carbon monoxide measurement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NRT proposition and exhaled CO measurement (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologic or cytologic diagnosis of NSCLC Stage IIIB or IV~* no prior systemic chemotherapy for advanced Non-Small Cell Lung Cancer~* Prior radiotherapy must be completed at least 4 weeks before study enrollment.~Exclusion Criteria:~* estimated life expectancy of 12 weeks~* a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease~* documented brain metastases unless the patient has completed successful local therapy for central nervous system metastases and has been off of corticosteroids for at least 2 weeks before enrollment~* significant weight loss (that is, \> 10%) over the previous 6 weeks before study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ipsilateral histologically confirmed invasive breast cancer~* Undergone total mastectomy and axillary dissection~* T1-2 and one to three axillary lymph nodes positive~* A minimum of 10 axillary nodes dissected~* Fit for chemotherapy(if indicated),endocrine therapy(if indicated)and postoperative irradiation~* Written,informed consent~Exclusion Criteria:~* Patients who undergone previous irradiation to the ipsilateral chest wall and supraclavicular region~* Previous or concurrent malignant other than non-melanomatous skin cancer~* Unable or unwilling to give informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- radiotherapy (Type: EXPERIMENTAL): radiotherapy of 50Gy/25/f/5w to the ipsilateral chest wall and supraclavicular region
- no radiotherapy (Type: ACTIVE_COMPARATOR): no radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients with Hemoglobin SS, SC, SB0thal or SB+thal~2. Patients with at least two episodes of primary nocturnal enuresis per week or four episodes over the two weeks prior to enrollment.~3. Patients with secondary enuresis who have been evaluated and cleared by a pediatric urologist as not having other etiologies of enuresis (e.g. overactive detrusor activity, a genitourinary anatomic abnormality)~Exclusion Criteria:~1. Patients with developmental delay or neurologic dysfunction secondary to stroke.~2. Patients with hypertension or underlying renal disease.~3. Patients with genitourinary anatomic abnormalities. Any prior renal ultrasound showing normal genitourinary anatomy is sufficient to clear a patient for the study.~4. Patients with daytime urinary incontinence~5. Patients with glucosuria on urinalysis.~6. Patients with secondary nocturnal enuresis who have not been evaluated by a pediatric urologist to rule out other etiologies of enuresis.~7. Patients who are pregnant.~8. Patients receiving another medicine for nocturnal enuresis (e.g. imipramine).

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Desmopressin (Type: None): 0.2mg tablets, dose titrated to effect
- Placebo (Type: None): Placebo Comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Two Treatments for Chronic Post Concussion Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mild Head Injury at least 3 months prior to treatment~* age 19 to 65 years~* grade 12 education~* proficiency with English language~Exclusion Criteria:~* Current Litigation

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Treatment As Usual (Type: ACTIVE_COMPARATOR): None
- Experimental (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Polycystic Liver Disease in Kidney Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (\> 18 years old) with stage IV or V chronic kidney due to ADPKD~* Primary kidney transplant~* Living or deceased donor kidney transplant~* Estimate total liver volume of 2.5 to 7.5 L~* In addition, at the discretion of the principal investigator(s), certain subjects with numerous liver cysts but with liver volume \< 2.5 liters may be enrolled.~Exclusion Criteria:~* Pediatric patients (\< 18 years of age)~* Patients with Body Mass Index (BMI) greater than or equal to 40 kg/m\^2~* Multi-organ transplant (kidney-liver, etc.)~* When people who have one blood type receive blood from someone with a different blood type, it may cause their immune system to react. This is called (ABO) incompatibility. ABO-incompatible or positive cross-match recipients~* Patients with severe hyperlipidemia (serum cholesterol \> 350 mg/dl or serum triglycerides \> 500 mg/dl)~* Patients with leukopenia (WBC \< 3000 10/ml)~* Patients unwilling to return to the transplant center for late follow-up visits~* Patients who are currently pregnant or breast-feeding or who expect to be pregnant during the study period~* Female patients of child bearing potential and men with sexual partners of child bearing potential who do not agree to use a medically accepted method of contraception during the study period~* Patients who are not eligible for Thymoglobulin induction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): Tacrolimus, mycophenolate mofetil, and prednisone
- Sirolimus Group (Type: ACTIVE_COMPARATOR): Sirolimus, mycophenolate mofetil, and prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed adult cancer patients from VICC and MMC~* Caregiver of enrolled newly diagnosed adult cancer patients from VICC and MMC~* No prior history of malignancy other than non-melanoma skin cancer~* Planned treatment for stages I - III cancer~* Treatment expected to be completed within 12 months~* English speaking~Exclusion Criteria:~* Prior history of malignancy other than non-melanoma skin cancer~* Patients treated with surgery alone will not be included~* Patients whose treatment is expected to last more than 12 months~* Non-English speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- NEST Intervention (Type: EXPERIMENTAL): Patients (PTs) and their caregivers (CGs) receive educational intervention, follow-up care, psychosocial assessment and care, and questionnaire administration interventions by completing psychosocial questionnaires and meeting with a nurse practitioner (NP) or nurse navigator (NN) for an initial survivorship care planning session to review the expected course of therapy and recovery, identify resources that may be needed and provide recommendations for follow-up. At the end of their treatment EOT), PTs and their CGs complete a 2nd set of questionnaires and meet with the NP/NN for a booster survivorship care planning session. They will receive an individualized final survivorship care plan and related materials. 2 months after EOT, PTs and their CGs complete a final set of questionnaires.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues